Ten co
mplexes of general for
mula [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-arene)Cl
2(L)], [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-arene)Cl(L)
2][X], and [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-arene)(L)
3][X]
2 (
mages/gifchars/eta.gif" BORDER=0 >
6-arene = benzene,
p-cy
mene; L = i
midazole, benzi
midazole,
N-
methyli
midazole,
N-butyli
midazole,
N-vinyli
midazole,
N-benzoyli
midazole; X = Cl, BF
4, BPh
4) have been prepared and characterized byspectroscopy. The structures of five representative co
mpounds have been established in the solid state bysingle-crystal X-ray diffraction. All the new co
mpounds were assessed by the sa
me in vitro screening assaysapplied to [i
midazole-H][
trans-RuCl
4(DMSO)(i
midazole)] (NAMI-A) and [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-arene)Cl
2(1,3,5-triaza-7-phosphaada
mantane)] (RAPTA) co
mpounds. It was found that the new co
mpounds show essentially thesa
me order of cytotoxicity as the RAPTA co
mpounds toward cancer cells. Several of the co
mpounds wereselective toward cancer cells in that they were less (or not) cytotoxic toward nontu
morigenic cells that areused to
model healthy hu
man cells. Thus, two of the co
mpounds, [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-
p-cy
mene)Cl(vinyli
mid)
2][Cl](vinyli
mid =
N-vinyli
midazole) and [Ru(
mages/gifchars/eta.gif" BORDER=0 >
6-benzene)(
mi
mid)
3][BF
4]
2 (
mi
mid =
N-
methyli
midazole), havebeen selected for a
more detailed in vivo evaluation.